135 related articles for article (PubMed ID: 17484896)
1. Ribavirin: is it a mutagen for hepatitis C virus?
Perelson AS; Layden TJ
Gastroenterology; 2007 May; 132(5):2050-2. PubMed ID: 17484896
[No Abstract] [Full Text] [Related]
2. Analysis of sequence configurations of the PKR-interacting HCV proteins from plasma and PBMC as predictors of response to interferon-alpha and ribavirin therapy in HIV-coinfected patients.
Bolcic F; Bull L; Martinez L; Reynoso R; Salomon H; Arduino R; Barnett B; Quarleri J
Intervirology; 2008; 51(4):261-4. PubMed ID: 18824873
[No Abstract] [Full Text] [Related]
3. A mutational shift from domain III to II in the internal ribosome entry site of hepatitis C virus after interferon-ribavirin therapy.
Ogata K; Kashiwagi T; Iwahashi J; Hara K; Honda H; Ide T; Kumashiro R; Kohara M; Sata M; Watanabe H; Hamada N
Arch Virol; 2008; 153(8):1575-9. PubMed ID: 18592133
[TBL] [Abstract][Full Text] [Related]
4. Mathematical modeling of HCV infection and treatment.
Dahari H; Shudo E; Ribeiro RM; Perelson AS
Methods Mol Biol; 2009; 510():439-53. PubMed ID: 19009281
[TBL] [Abstract][Full Text] [Related]
5. Ribavirin posology, observance, and sustained virologic response.
Couzigou P; Foucher J; Castera L; De Ledinghen V
Clin Gastroenterol Hepatol; 2008 Mar; 6(3):367. PubMed ID: 18063421
[No Abstract] [Full Text] [Related]
6. Virology of hepatitis B and C viruses and antiviral targets.
Pawlotsky JM
J Hepatol; 2006; 44(1 Suppl):S10-3. PubMed ID: 16338022
[TBL] [Abstract][Full Text] [Related]
7. Influence of mutagenesis and viral load on the sustained low-level replication of an RNA virus.
Perales C; Agudo R; Manrubia SC; Domingo E
J Mol Biol; 2011 Mar; 407(1):60-78. PubMed ID: 21256131
[TBL] [Abstract][Full Text] [Related]
8. 3-Amino-2(5H)furanones as inhibitors of subgenomic hepatitis C virus RNA replication.
Iannazzo D; Piperno A; Romeo G; Romeo R; Chiacchio U; Rescifina A; Balestrieri E; Macchi B; Mastino A; Cortese R
Bioorg Med Chem; 2008 Nov; 16(21):9610-5. PubMed ID: 18835180
[TBL] [Abstract][Full Text] [Related]
9. [Antiviral mechanism of ribavirin against RNA virus].
Hamano K; Sakamoto N; Enomoto N
Nihon Rinsho; 2004 Jul; 62 Suppl 7(Pt 1):459-62. PubMed ID: 15359841
[No Abstract] [Full Text] [Related]
10. [BMS-790 052 - an oral antiviral hepatitis C antiviral in the pipeline].
Schmitz J
Pharm Unserer Zeit; 2011 Jan; 40(1):8-9. PubMed ID: 21194074
[No Abstract] [Full Text] [Related]
11. Co-infections. Predicting recovery from hep C.
TreatmentUpdate; 2008; 20(4):10-1. PubMed ID: 19248276
[No Abstract] [Full Text] [Related]
12. Ribavirin up-regulates the activity of double-stranded RNA-activated protein kinase and enhances the action of interferon-alpha against hepatitis C virus.
Liu WL; Su WC; Cheng CW; Hwang LH; Wang CC; Chen HL; Chen DS; Lai MY
J Infect Dis; 2007 Aug; 196(3):425-34. PubMed ID: 17597457
[TBL] [Abstract][Full Text] [Related]
13. Novel hepatitis C drugs in current trials.
Kronenberger B; Welsch C; Forestier N; Zeuzem S
Clin Liver Dis; 2008 Aug; 12(3):529-55, viii. PubMed ID: 18625427
[TBL] [Abstract][Full Text] [Related]
14. Hepatitis C virus virology and new treatment targets.
Meier V; Ramadori G
Expert Rev Anti Infect Ther; 2009 Apr; 7(3):329-50. PubMed ID: 19344246
[TBL] [Abstract][Full Text] [Related]
15. Hepatitis C virus resistance to antiviral therapy.
Pawlotsky JM
Hepatology; 2000 Nov; 32(5):889-96. PubMed ID: 11050035
[No Abstract] [Full Text] [Related]
16. Treatment and vaccination for hepatitis C: present and future.
Jawaid A; Khuwaja AK
J Ayub Med Coll Abbottabad; 2008; 20(1):129-33. PubMed ID: 19024206
[TBL] [Abstract][Full Text] [Related]
17. Rapid virological response in hepatitis C virus genotype 1 and early ribavirin exposure.
Dai CY; Chuang WL; Huang JF; Hsieh MY; Yu ML
Hepatology; 2008 Aug; 48(2):692-3; author reply 693-4. PubMed ID: 18666250
[No Abstract] [Full Text] [Related]
18. [Hepatitis C virus--structure, replication and therapeutical opportunities and the phenomenon of resistance].
Kowala-Piaskowska A
Postepy Biochem; 2006; 52(4):399-407. PubMed ID: 17536509
[TBL] [Abstract][Full Text] [Related]
19. Treatment predictors of a sustained virologic response in hepatitis B and C.
Kau A; Vermehren J; Sarrazin C
J Hepatol; 2008 Oct; 49(4):634-51. PubMed ID: 18715665
[TBL] [Abstract][Full Text] [Related]
20. Cyclic phosphoramidates as prodrugs of 2'-C-methylcytidine.
Meppen M; Pacini B; Bazzo R; Koch U; Leone JF; Koeplinger KA; Rowley M; Altamura S; Di Marco A; Fiore F; Giuliano C; Gonzalez-Paz O; Laufer R; Pucci V; Narjes F; Gardelli C
Eur J Med Chem; 2009 Sep; 44(9):3765-70. PubMed ID: 19493593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
